Disclosed herein is a T-helper cell (T.sub.H-GM cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating T.sub.H-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying T.sub.H-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-T.sub.H-GM-mediated (e.g., TNF--mediated) inflammatory disorders, are also provided.

A method for determining healing status of a wound is provided comprising: i) quantifying the expression level of GM-CSF or MMP-13, and optionally one or more additional biomarkers, in a wound tissue sample or wound fluid sample from a wound of a mammalian subject; and ii) comparing the expression level of GM-CSF or MMP-13 of the wound tissue sample or wound fluid sample to a threshold level and determining that the wound is non-healing if the level of GM-CSF or MMP-13 exceeds the threshold level.

Disclosed herein is a T-helper cell (T.sub.H-GM cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating T.sub.H-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying T.sub.H-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-T.sub.H-GM-mediated (e.g., TNF--mediated) inflammatory disorders, are also provided.

The present invention relates to a method for prediction of response to cardiovascular regeneration comprising the use of biomarkers. Further, the present invention relates to a combination of the biomarkers for use in a method for prediction of response to cardiovascular regeneration, a computer device to perform a method according to the present invention and a device adapted for carrying out the inventive method.

Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

A method for manufacturing a measuring kit is disclosed. The method for manufacturing a measuring kit includes steps of providing a carrier including a substrate having a surface; coating a silane onto the surface of the substrate; providing an organic molecule; adding the organic molecule onto the carrier; outputting a microwave energy by a coaxial cable; and emitting the microwave energy through a radiator to microwave the carrier and the organic molecule uniformly to coat the organic molecule onto the carrier carrying the silane, wherein the measuring kit is used to apply an enzyme-linked immunosorbent assay.

Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.

Diagnostic screening tests that can be used to identify if a patient is a good candidates for an implantable vagus nerve stimulation device. One or more analyte, such as a cytokine or inflammatory molecule, can be measured from a blood sample taken prior to implantation of a vagus nerve stimulator to determine the patient's responsiveness to VNS for treatment of an inflammatory disorder.

The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy and a method of treatment to facilitate same. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes and the identification of therapeutic targets. Taught herein is a composition comprising reagents required for prognostic evaluation and treatment.

The present disclosure provides iPSC-derived microglia comprising a protective CD33 allele. Further provided herein are assays for screening analytes and genes associated with the protective CD33 allele.